Atria Investments Inc Buys Shares of 10,417 Travere Therapeutics, Inc. $TVTX

Atria Investments Inc bought a new position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,417 shares of the company’s stock, valued at approximately $154,000.

Several other hedge funds and other institutional investors have also modified their holdings of TVTX. Caitong International Asset Management Co. Ltd bought a new stake in shares of Travere Therapeutics during the 1st quarter valued at about $62,000. Cerity Partners LLC bought a new position in shares of Travere Therapeutics during the first quarter valued at approximately $217,000. E Fund Management Co. Ltd. grew its holdings in shares of Travere Therapeutics by 8.6% during the first quarter. E Fund Management Co. Ltd. now owns 13,553 shares of the company’s stock valued at $243,000 after purchasing an additional 1,072 shares during the last quarter. CWM LLC raised its position in shares of Travere Therapeutics by 48.5% during the 1st quarter. CWM LLC now owns 13,964 shares of the company’s stock worth $250,000 after purchasing an additional 4,558 shares during the period. Finally, Entropy Technologies LP lifted its holdings in shares of Travere Therapeutics by 18.6% in the 1st quarter. Entropy Technologies LP now owns 14,592 shares of the company’s stock worth $261,000 after purchasing an additional 2,292 shares during the last quarter.

Travere Therapeutics Trading Up 1.8%

Travere Therapeutics stock opened at $34.50 on Friday. Travere Therapeutics, Inc. has a 12-month low of $12.91 and a 12-month high of $36.76. The company has a debt-to-equity ratio of 9.50, a current ratio of 2.00 and a quick ratio of 1.98. The stock has a market capitalization of $3.09 billion, a PE ratio of -16.91 and a beta of 0.90. The firm has a 50 day simple moving average of $27.66 and a 200-day simple moving average of $20.60.

Travere Therapeutics (NASDAQ:TVTX) last released its earnings results on Thursday, October 30th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.59. The firm had revenue of $164.86 million during the quarter, compared to the consensus estimate of $106.09 million. Travere Therapeutics had a negative return on equity of 717.68% and a negative net margin of 50.64%.The firm’s revenue for the quarter was up 162.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.70) earnings per share. As a group, equities research analysts expect that Travere Therapeutics, Inc. will post -1.4 EPS for the current fiscal year.

Insiders Place Their Bets

In other Travere Therapeutics news, insider Elizabeth E. Reed sold 10,000 shares of the business’s stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $25.00, for a total value of $250,000.00. Following the sale, the insider directly owned 89,878 shares in the company, valued at approximately $2,246,950. The trade was a 10.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Peter Heerma sold 5,591 shares of the company’s stock in a transaction dated Friday, October 31st. The shares were sold at an average price of $35.00, for a total transaction of $195,685.00. Following the completion of the sale, the insider directly owned 119,071 shares of the company’s stock, valued at $4,167,485. The trade was a 4.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 223,941 shares of company stock valued at $7,221,380. 4.19% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts have weighed in on TVTX shares. Zacks Research lowered Travere Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday. Piper Sandler upped their price target on shares of Travere Therapeutics from $26.00 to $35.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 4th. Wells Fargo & Company increased their price objective on shares of Travere Therapeutics from $27.00 to $35.00 and gave the stock an “overweight” rating in a report on Thursday, September 11th. Stifel Nicolaus boosted their target price on shares of Travere Therapeutics from $20.00 to $25.00 and gave the company a “hold” rating in a research note on Friday, September 12th. Finally, Wedbush upped their target price on shares of Travere Therapeutics from $30.00 to $32.00 and gave the stock an “outperform” rating in a research report on Thursday, August 7th. Thirteen analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $38.71.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.